成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Metabolic Enzyme/Protease Autophagy
  3. FXR Endogenous Metabolite Autophagy
  4. Chenodeoxycholic Acid

Chenodeoxycholic Acid  (Synonyms: 鵝去氧膽酸; CDCA)

目錄號(hào): HY-76847 純度: 99.90%
COA 產(chǎn)品使用指南 技術(shù)支持

Chenodeoxycholic Acid 是一種疏水初級(jí)膽汁酸，能夠活化核受體 FXR，該受體與膽固醇代謝有關(guān)。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Chenodeoxycholic Acid Chemical Structure

Chenodeoxycholic Acid Chemical Structure

CAS No. : 474-25-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥500
In-stock
500 mg ￥700
In-stock
1 g ￥900
In-stock
5 g ￥1300
In-stock
10 g   詢價(jià)  
50 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Chenodeoxycholic Acid:

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

IC50 & Target

Human Endogenous Metabolite

 

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
Caco-2 IC50
106 μM
Compound: CDCA
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 24332653]
CHO EC50
15.6 μM
Compound: CDCA
Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay
Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay
[PMID: 31268316]
CHO EC50
6.71 μM
Compound: 4, CDCA
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
[PMID: 18307294]
CHO EC50
6.71 μM
Compound: 2, CDCA
Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay
Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay
[PMID: 17685603]
COS-1 EC50
13 μM
Compound: 4, CDCA
Agonist activity at human FXR expressed in COS1 cells by luciferase assay
Agonist activity at human FXR expressed in COS1 cells by luciferase assay
[PMID: 18307294]
COS-1 EC50
13 μM
Compound: 2, CDCA
Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay
[PMID: 17685603]
COS-1 EC50
13 μM
Compound: 3, CDCA
Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay
Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay
[PMID: 20014870]
GBM IC50
> 50 μM
Compound: 1c, CDCA, chenodeoxycholic acid
Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay
[PMID: 20381215]
HCT-116 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
HCT-116 IC50
> 50 μM
Compound: 1c, CDCA, chenodeoxycholic acid
Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay
[PMID: 20381215]
HEK293 EC50
11.7 μM
Compound: 3, CDCA
Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells
Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells
[PMID: 16617018]
HEK293 EC50
16.8 μM
Compound: CDCA
Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay
Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay
[PMID: 22014750]
HEK293 EC50
16.8 μM
Compound: 2, CDCA
Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay
Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay
[PMID: 22018919]
HEK293 EC50
27 μM
Compound: 5, CDCA
Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay
Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay
[PMID: 22583617]
HEK293 EC50
27 μM
Compound: CDCA
Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity
Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity
[PMID: 17292610]
HEK293 EC50
6.1 μM
Compound: 2, CDCA
Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay
Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay
[PMID: 25735208]
HEK-293T EC50
> 150 μM
Compound: CDCA
Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
[PMID: 26774929]
HEK-293T IC50
> 50 μM
Compound: CDCA
Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
[PMID: 26774929]
HeLa EC50
18 μM
Compound: 1, CDCA
Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay
Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay
[PMID: 25934227]
HeLa EC50
18 μM
Compound: 1, CDCA
Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay
Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay
[PMID: 25255039]
HepG2 EC50
20 μM
Compound: 1; CDCA
Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay
Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay
[PMID: 30996771]
HET-1A CC50
216 μM
Compound: 1, CDCA
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 20713311]
HT-1080 IC50
130.1 μM
Compound: CDCA
Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HT1080 cells assessed as cell viability after 24